Pfizer Inc. (PFE)

Drug stocks are poised to outperform in 2025, driven by conservative valuations and a research renaissance in key therapeutic areas. US healthcare spending growth and transformative GLP-1 therapies, e...

Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.

Did you know that if you have a reliable income stock that yields 6%, you would only need to invest about $16,700 in it to collect $1,000 in dividends over the course of a full year? The average stock...

Does the government shutdown have you feeling queasy about investing in stocks? It's understandable, but history says your portfolio's going to be just fine.

The biggest risks facing pharmaceutical companies in recent times haven't had to do with clinical trials or winning regulatory approval. Instead, investors have worried about President Donald Trump's ...

Down-to-the wire team negotiations capped a long dance between President Trump and CEO Albert Bourla.

Pfizer Inc. has secured an MFN pricing deal with the White House, easing recent tariff and drug repricing concerns while affording a win for Trump. PFE's solid dividend yield of >6% provides a robust ...

The big draw for most investors with Pfizer (PFE 6.77%) today is likely to be its lofty 7.2% dividend yield. That compares to 1.2% for the S&P 500 index and about 1.3% for the average pharmaceutical s...

The company's accord with the president clears a cloud over the whole sector.

Dividend yields are historically low these days. The S&P 500 yields less than 1.2%, which is near its lowest level on record.